BREVAGenplus logo
BREVAGenplus(R) Offers a Solution to Physicians Concerned About the Revised Breast Cancer Screening Guidelines from the American Cancer Society (ACS)
02. November 2015 10:35 ET | Genetic Technologies Group
CHARLOTTE, N.C., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Phenogen Sciences, Inc., the U.S. subsidiary of Australia-based Genetic Technologies Limited (NASDAQ:GENE) and maker of BREVAGenplus, today commented...
BREVAGenplus logo
PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK
28. Mai 2015 14:34 ET | Genetic Technologies Group
CHARLOTTE, N.C., May 28, 2015 (GLOBE NEWSWIRE) -- Phenogen Sciences, Inc., the U.S. subsidiary of Australia-based Genetic Technologies Limited (NASDAQ: GENE), today notes with interest the special...
BREVAGenplus logo
ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK
11. Mai 2015 11:36 ET | Genetic Technologies Group
ROCKVILLE, Md., May 11, 2015 (GLOBE NEWSWIRE) -- Carolynn Young, MD, Board-Certified Obstetrician and Gynecologist, announces that Rockville Gynecology is now offering BREVAGenplus®, a...
BREVAGenplus logo
PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT
16. Dezember 2014 11:23 ET | Genetic Technologies Group
SAN ANTONIO, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Phenogen Sciences, Inc. (www.phenogensciences.com) announces that findings from a new research study show that adding a panel of 77 single-nucleotide...
BREVAGen reclassified 64 percent of above average Gail risk subjects
CONTEMPORARY OBSTETRICS AND GYNECOLOGY OF DAYTON ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
30. September 2013 10:34 ET | Genetic Technologies Group
DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk...
BREVAGen reclassified 64 percent of above average Gail risk subjects
PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
16. September 2013 10:08 ET | Genetic Technologies Group
SAN FRANCISCO, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W....
BREVAGen Logo_edit
OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
26. August 2013 13:06 ET | Genetic Technologies Group
SUNBURY, PA., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the...
BREVAGen_reclassified
THE HEWITT CENTER FOR BREAST WELLNESS AT GRIFFIN HOSPITAL IN DERBY, CT LAUNCHES HIGH-RISK PROGRAM INCLUDING STATE-OF-THE-ART BREAST CANCER SCREENING OPTIONS
24. Juni 2013 12:16 ET | Genetic Technologies Group
DERBY, Conn., June 24, 2013 (GLOBE NEWSWIRE) -- Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness in Derby, CT, has launched a high-risk breast cancer program that includes...
BREVAGen chart
STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE
15. April 2013 12:06 ET | Genetic Technologies Group
CHARLOTTE, N.C., April 15, 2013 (GLOBE NEWSWIRE) -- Phenogen Sciences, Inc. recently presented study results demonstrating that BREVAGen™, a first-in-class, scientifically-validated predictive...
BREVAGen chart
The Centers for Women's Health in Stamford CT Pioneers Breast Cancer Risk Assessment
18. März 2013 12:14 ET | Genetic Technologies Group
STAMFORD, Conn., March 18, 2013 (GLOBE NEWSWIRE) -- Dr. Joel Evans, Founder and Director of The Center for Women's Health, is one of the first physicians in the nation to make the BREVAGen™...